MEIP

MEI Pharma (MEIP)

MEI Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MEIP

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/22	05 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MEIP	MEI Pharma Inc
2024/05/22	02 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2024/05/21	05 : 00	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MEIP	MEI Pharma Inc
2024/05/10	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2024/05/10	05 : 02	Business Wire	MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights	NASDAQ:MEIP	MEI Pharma Inc
2024/05/10	05 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MEIP	MEI Pharma Inc
2024/04/11	21 : 02	Business Wire	MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344	NASDAQ:MEIP	MEI Pharma Inc
2024/04/11	21 : 00	Business Wire	MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	NASDAQ:MEIP	MEI Pharma Inc
2024/04/10	21 : 00	Business Wire	MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum	NASDAQ:MEIP	MEI Pharma Inc
2024/03/26	21 : 00	Business Wire	MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia	NASDAQ:MEIP	MEI Pharma Inc
2024/02/29	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:MEIP	MEI Pharma Inc
2024/02/22	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2024/02/21	07 : 33	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:MEIP	MEI Pharma Inc
2024/02/14	07 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2024/02/14	07 : 05	Business Wire	MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights	NASDAQ:MEIP	MEI Pharma Inc
2024/01/18	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2024/01/17	07 : 00	Business Wire	MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024	NASDAQ:MEIP	MEI Pharma Inc
2024/01/13	06 : 00	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:MEIP	MEI Pharma Inc
2024/01/13	06 : 00	Edgar (US Regulatory)	Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]	NASDAQ:MEIP	MEI Pharma Inc
2023/12/27	07 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2023/12/23	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2023/12/21	11 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MEIP	MEI Pharma Inc
2023/12/21	11 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MEIP	MEI Pharma Inc
2023/12/19	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2023/12/12	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2023/12/12	02 : 00	Business Wire	MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023	NASDAQ:MEIP	MEI Pharma Inc
2023/11/15	10 : 59	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:MEIP	MEI Pharma Inc
2023/11/10	06 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:MEIP	MEI Pharma Inc
2023/11/10	06 : 05	Business Wire	MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights	NASDAQ:MEIP	MEI Pharma Inc
2023/11/10	06 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MEIP	MEI Pharma Inc